Why Purchase Mobilized Leukopaks from Charles River?

  • Our extensive and recallable donor network is capable of accommodating the most rigorous research criteria
  • With our recallable donor pool, reduce donor-to-donor variation while obtaining a more reliable source of CD34+ hematopoietic cells
  • High CD34+ HSPCs and mononuclear cell viability
  • Low red blood cell contamination
  • Our donor center is fully compliant with all necessary regulations, including FDA registration, AABB and CLIA certification, and is state-licensed
  • Our experienced medical team is equipped to safely conduct fresh mobilized leukapheresis through six different dosing regimens.

Download Catalog

Explore Mobilized Leukopaks, Mobilizing Agents and Dosing Regimens

Our mobilized leukopaks and CD34+ HSPCs derived from mobilized peripheral blood are available using mobilization with G-CSF (Neupogen® or FDA-approved biosimilars) alone, Plerixafor (Mozobil® or FDA-approved biosimilars) alone, or in combination. A brief description of these mobilizing agents and their mechanism of action is detailed below. 

Along with choosing the mobilization agent(s) that best suits the downstream application, researchers can also select different dosing regimens that include varying mobilization durations and collection days. Mobilization agents, dosage, dosing schedule, and number of collections all impact total stem cell yields. In general, increasing the mobilization duration and including dual mobilization regimes (G-CSF + Plerixafor) in conjunction with multiple day collections, will result in substantial benefits in terms of CD34+ stem cell yields in the mobilized leukopaks.

  • Granulocyte-Colony Stimulating Factor (G-CSF)

    Dosing Regimen

    Product CodeMobilizing Agent/ReagentDays 1 – 4Day 5Day 6
    M001F-GCSF-2G-CSF (4-day stimulation, 1 bag)G-CSFCollect–
    M001F-GCSF-3G-CSF (5-day stimulation, 1 bag)G-CSFG-CSFCollect
    M001F-GCSF-4-KITG-CSF (5-day stimulation, 2 bags)G-CSFCollect
    G-CSF
    		Collect

    Contact us if you don’t see a specific product, size, or format, or would like to customize your request.

    Your company or academic institution may be eligible for pricing discounts. Government labs located in the United States are also eligible for GSA MAS discounts. Request a quote to find out more.

    REQUEST A QUOTE/ORDER

  • Plerixafor
      Day
    Product CodeMobilized Agent/Reagent 123456
    M001F-MOZ-1Plerixafor
    (1-day stimulation, 1 bag)    		Plerixafor (AM) 
    Collect (PM)    		Option for injection in PM day 1
    and collection in AM day 2
    M001F-MOZ-3-KITPlerixafor
    (1-day stimulation, 2 bags)    		Plerixafor (AM) 
    Collect (PM)    		Collect (AM)––––
    M001F-MOZ-2-KITPlerixafor
    (2-day stimulation, 2 bags)    		Plerixafor (AM)
    Collect (PM)    		Plerixafor (AM) 
    Collect (PM)    		Option for injections in PM days 1 and 2 and collection in AM days 2 and 3

    Contact us if you don’t see a specific product, size, or format, or would like to customize your request.

    Your company or academic institution may be eligible for pricing discounts. Government labs located in the United States are also eligible for GSA MAS discounts. Request a quote to find out more.

    REQUEST A QUOTE/ORDER

     

  • Dual Mobilization: G-CSF + Plerixafor
      Days
    Product CodeMobilized Agent/Reagent 1 – 3456
    M001F-GCSF-MOZ-1G-CSF + Plerixafor
    (5-day stimulation, 1 bag)    		G-CSFG-CSF G-CSF
    Plerixafor (PM)    		Collect
    M001F-GCSF-MOZ-2KTG-CSF + Plerixafor
    (5-day stimulation, 2 bags)    		G-CSFG-CSF 
    Plerixafor (PM)    		G-CSF 
    Collect 
    Plerixafor (PM)    		Collect

    Contact us if you don’t see a specific product, size, or format, or would like to customize your request.

    Your company or academic institution may be eligible for pricing discounts. Government labs located in the United States are also eligible for GSA MAS discounts. Request a quote to find out more.

    REQUEST A QUOTE/ORDER

cover of the ultimate leukopak guidebook

GUIDEBOOK
How Much Do You Really Know About Leukopaks?
Find out what they are and why they are important for immune research and cell therapy development. Our comprehensive guide covers best practices, considerations, applications, and in-depth characterizations for leukopak collections.
Download Guidebook

 

Mobilized Leukopak Study Conducted by Charles River

 

Frequently Asked Questions (FAQs) About Mobilized Leukopaks

  • What are mobilized leukopaks?

    Mobilized peripheral blood is the blood circulating throughout the body that has been treated with mobilizing agent(s) such as Plerixafor and/or G-CSF. The term "mobilization" refers to the recruitment of CD34+ hematopoietic stem and progenitor cells from the bone marrow into the blood stream where they can be collected via leukapheresis.

  • How are mobilized leukopaks collected?

    Our CD34+ hematopoietic stem cell-rich mobilized leukapheresis products are collected under strict SOPs using continuous flow centrifugal technology (Spectra Optia® Apheresis System) directly into a sterile collection bag containing ACD-A anticoagulant. All mobilized leukopaks are collected from healthy human donors who have provided their consent under an IRB-approved protocol. Our donor center is California state-licensed, FDA-registered, and accredited by CLIA and AABB.

  • How does G-CSF mobilize CD34+ hematopoietic stem and progenitor cells?

    G-CSF (Neupogen® and its biosimilars) directly increases the production of granulocytes and their precursors including CD34+ stem cells. G-CSF enhances release of CD34+ HSPCs into the peripheral blood by decreasing the expression of stromal cell-derived factor-1 (SDF-1α), a protein that helps anchor hematopoietic stem cells to the bone marrow matrix. G-CSF also increases the number of proteases that directly cleave SDF-1α and HSPC interactions, promoting the release of CD34+ stem cells from the bone marrow into the peripheral bloodstream. 

    A study done by Stroncek et al. in 1996 reported that in healthy normal donors, peak levels of CD34+ stem cells were reached on the sixth day of mobilization (after daily injections for five days), approximately twice the levels seen on the fourth day.

  • How does Plerixafor mobilize CD34+ hematopoietic stem and progenitor cells?

    During early pharmacokinetic studies done in 2000 by Hendrix et al., it was reported that Plerixafor when administered to normal subjects, increased CD34+ hematopoietic stem cell counts unexpectedly, with the peak reached approximately six hours after administration. The method of Plerixafor (Mozobil® and its biosimilars) mobilization was shown to be direct antagonism of SDF-1α competitively binding to its natural ligand CXCR4 on bone marrow stromal cells; with the binding blocked, CD34+ cells are released into the circulation.

  • Is it better to use both mobilizing agents (G-CSF and Plerixafor) in tandem?

    When used in combination, higher numbers of CD34+ hematopoietic stem cells are released into the circulation and available for collection than with either mobilizing agent alone. The two agents work in concert with G-CSF increasing CD34+ stem cell production in the bone marrow and Plerixafor enhancing their release into the blood.

    Studies have shown that G-CSF and Plerixafor boost different progenitor cell populations with the frequency of more primitive HSPC types increasing with a combination of G-CSF and Plerixafor. In addition, mobilization of CD34+ stem cells into peripheral blood occurs more rapidly with the use of both drugs in a combined treatment.

  • Why should I use mobilized leukopaks?

    Currently, mobilized peripheral blood is the predominant source of HSPCs for basic research and clinical use. Other sources of CD34+ stem cells include bone marrow aspirate and umbilical cord blood. The preference for using a mobilized leukopak is primarily due to accessibility, relative ease of sourcing, and increased recallability potential for the donors leading to source material consistency. In addition, mobilized leukopak volumes, usually 200 to 400 mLs, are significantly greater than for either cord blood or bone marrow collections, normally leading to higher overall yields of CD34+ stem cells.

  • What’s the average CD34+ hematopoietic stem cell yield from a Charles River mobilized leukopak collection?

    For a detailed breakdown on stem cell yields and dosing regimens, please download our white paper: A Comprehensive Analysis of CD34+ Stem Cell Mobilization Regimens. It offers a thorough examination of CD34+ stem cell mobilization, including its history and the various factors that can affect stem cell yields in mobilized leukopaks, such as different mobilization agents, dosing schedules, and processed blood volume.